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Abstract
This commentary article conveys the views of the board of the Nanomedicine and Nanoscale Delivery Focus Group
of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in
halting funding for the Centers of Cancer Nanotechnology Excellence (CCNEs), and the subsequent editorial articles
that broadened this discussion.
Keywords Nanomedicine . Nanotechnology . Clinical translation . Reproducibility . Cancer therapy
On May 2019, the journal Science reported that the
United States National Cancer Institute (NCI) would
halt funding for the Centers of Cancer Nanotechnology
Excellence (CCNEs) [1]. This decision of the NCI trig-
gered news headlines and was followed by an impactful
commentary piece on nanomedicine, authored by Kinam
Park, the former Editor-in-Chief of the Journal of
Controlled Release [2]. Park conveyed that the decision
was timely and represented the “beginning of the end”
of the nanomedicine hype, laying out a series of argu-
ments to support his statement. In a follow-up letter to
the editor of the same journal [3], Piotr Grodzinski ex-
plained that the NCI uses a pool of “set aside” funds to
support, for a limited period of time, the growth of
emerging fields. This financial support is intended to
make the field strong enough and, if worthy of invest-
ment, capable of competing via other funding mecha-
nisms [3]. The NCI “set aside” funds supported the
CCNEs for 15 years, during which two judicious deci-
sions of renewal were followed by gradual budget cut-
backs. The decrease in NCI funding to the CCNEs has
been accompanied by a global growth in cancer nano-
technology research, resulting in a more than twofold
increase in the number of cancer nanotechnology-
related grant applications awarded worldwide between
2008 and 2018, as reported by Grodzinski [3]. Now that
the field has matured enough, it is time for the antici-
pated non-renewal of the NCI financial support of the
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CCNEs under this program. In view of these events, we
would like to take this opportunity to communicate the
views of the board of the Nanomedicine and Nanoscale
Delivery Focus Group of the Controlled Release
Society.1
An extensive body of evidence has demonstrated the ability
of several nanomedicines (both non-targeted and targeted) to
increase active payload concentrations at the target site (e.g.,
tumor) [4–6], as well as to reduce toxicity and enhance ther-
apeutic efficacy compared with free drugs in preclinical stud-
ies [7–9]. More importantly, studies in humans support the
ability of nanoparticle-based therapies to enhance active pay-
load accumulation in tumors, and to improve safety and/or
anticancer efficacy [10–12]. Over the years, many
nanomedicines have received clinical approval based on im-
proved safety with equivalent efficacy. For example, Doxil®
(liposomal doxorubicin) was approved for multiple myeloma
due to a better safety profile compared with free doxorubicin
[13]. In terms of therapeutic efficacy in clinical studies, there
are also several nanomedicines that outperform their free drug
counterparts. For example, in some phase III clinical trials for
breast cancer, Abraxane® (albumin-bound paclitaxel
nanoparticle) was shown to cause better treatment responses
compared with free paclitaxel [14, 15]. Another example is the
approval of Vyxeos® (liposomal daunorubicin and
cytarabine); a phase III clinical trial for high-risk acute mye-
loid leukemia (AML) demonstrated that Vyxeos® resulted in a
median overall survival of 9.56 months compared with
5.95 months with free cytarabine and daunorubicin combina-
tion therapy (standard of care) [16]. In addition,
nanotechnology-enabled cancer therapies do not merely focus
on placing drugs at the tumor site, but also seek to provide
novel therapeutic approaches in line with the discovery of new
disease mechanisms and the precision oncology concept, and
to restrict the interplay with other non-tumor cells involved in
tumor progression and dissemination [17, 18]. Hence, an im-
proved understanding of the disease mechanisms will enable
the development of more efficient nanomedicines with mech-
anisms of action beyond tumor nanoparticle accumulation
[19, 20]. For instance, nanoparticles are currently being ex-
plored in the fields of adoptive cell therapy and immune mod-
ulation in various stages of preclinical and clinical develop-
ment [21]. Moreover, recent preclinical studies and clinical
trials have shown benefits of combination therapies, and par-
ticularly, the ability of nanoparticles to simultaneously deliver
therapeutic agents, such as small molecules, genetic material,
and biologics [22].
A careful analysis of the current nanomedicine market and
development pipeline leaves little margin to question the value
proposition that nanomedicines already play in healthcare.
There are current ly over 50 nanomedicines and
nanotechnology-based medical products approved by regula-
tory bodies worldwide for a variety of indications [23–25].
Some additional examples of nanomedicines used in cancer
therapy include Onivyde® (liposomal irinotecan) or Hensify®
(hafnium oxide nanoparticles). There are also many
nanomedicines that are used for indications other than oncol-
ogy, such as the “classic” AmBisome® (liposomal
amphotericin B) for fungal infections, or the recently ap-
proved Onpattro® (small interfering RNA-lipid nanoparticles)
for hereditary transthyretin amyloidosis (ATTR). The latter
constitutes the first-in-class RNA interference (RNAi) thera-
peutic, paving the way for many novel nanotechnology-based
gene silencing therapeutics [26]. Additionally, an estimated
100 nanoparticle-based products are in clinical trials [24,
27], of which 18 started in the past 3 years, legitimating the
idea that “the interest and pursuit of successful nanoparticle
technologies continues,” highlighted by Anselmo and
Mitragotri in their most recent update on nanoparticles used
in clinical practice [28]. Indeed, many companies have been
actively developing nanomedicines over the past years, and
investing billions of dollars, either in developing their own
pipeline or through acquisitions. These include small- to
mid-sized firms focused on research and development
(R&D), as well as multinational companies like Pfizer, Eli
Lilly and Company, Novartis, and Sanofi, to name a few.
Moreover, a promising shift within the nanomedicine research
community is the additional focus on cardiovascular [29], au-
toimmune [30, 31], neurological [32], infectious [33], and
genetic and rare diseases [34]. RNA-based synthetic vaccines
are another emerging area with high potential for
nanomedicine [35–37]. Hence, public and private science
funders and policy makers should drive such diversification
to stimulate the pursuit of nanomedicines for clinical applica-
tions beyond cancer.
Challenges involved in the clinical translation of
nanomedicines include the lack of batch-to-batch reproduc-
ibility, long-term stability of some products, complexity of
the manufacturing processes, and maintenance of sterile con-
ditions. There is also a lag between continuous scientific ad-
vances and regulatory guidance, namely regarding the specific
requirements that are necessary for nanomedicine products to
advance for clinical trials. In addition, the lack of appropriate
controls and poorly defined critical quality attributes, as well
as the absence of clinically relevant animal models that truly
recapitulate the mechanisms of action of nanomedicines in
humans, have prevented widespread clinical translation [38,
39]. The limitations imposed by too simplistic approaches or
too complex models that hinder reliable interpretation of data
call attention to the need for standardization and stratification
of methodology [40]. The gradual implementation of univer-
sally standardized practices could promote more accurate
reporting of materials and methodologies, and could change
1 https://www.controlledreleasesociety.org/focus-groups/nanomedicine-and-
nanoscale-delivery-nnd
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the paradigm for many nanotechnology products that already
exist [41, 42]. On top of this, improving the clinical impact of
nanomedicines demands “smart thinking and rational and real-
istic reasoning,” as stated by van der Meel et al. in a recently
published perspective article in Nature Nanotechnology [43]. In
this sense, and particularly in the case of cancer therapy, patient
stratification, rational drug selection, the use of combination
therapies, and the targeting of the adaptive immune system
are key for addressing scientific and medical questions that will
potentiate the exploitation and, most importantly, the translation
of nanomedicines into the clinic. As stated in Park’s commen-
tary, “meaningful work” on nanomedicine rather than “focusing
on publications” needs to be prioritized. However, this is not an
idiosyncrasy of the nanomedicine field, but rather a transversal
problem of scientific endeavors in general. In an ideal scenario,
academic institutions should be efficiently working together
with industry partners and regulatory agencies to bring innova-
tive nanomedicines to clinical practice.
In a recent editorial in the journal Nature Biomedical
Engineering titled “Targeting for delivery,” the clinical trans-
lation of cancer nanomedicines was addressed, and re-
searchers were designated as those that “feel that there is a
‘delivery problem’” and those “who are optimistic” [44]. In
light of the facts outlined in the present commentary article,
the board of the Nanomedicine and Nanoscale Delivery Focus
Group of the Controlled Release Society falls into the second
group. Delivery systems are continuously evolving with an
increased understanding of complexities of human diseases
like cancer. We have grounds for optimism and reasons to
allude to the Gartner hype cycle [45]. As for any other poten-
tial breakthrough, the disillusionment around nanomedicines
for cancer applications is not more than a natural state after a
“peak of inflated expectations.” However, the outcomes start
to crystallize, and the “plateau of productivity” seems more
realistic than a foreseeable ambition [46].
Despite the fact that several early promises of
nanomedicine are still left unmet, the solid contributions of
nanotechnology to the cancer therapeutics and diagnostics,
and more generally on human health, cannot be ignored
[46]. This is not the “beginning of the end,” but the turnaround
from academic development and preclinical studies to system-
atic and translational approaches, industrial development, and
clinical trials. We believe that nanomedicine as a research field
is not languishing or doomed. On the contrary, as the body of
fundamental knowledge on the complex interactions between
nanomaterials and host increases, the likelihood of additional
and innovative nanotechnology-based products being devel-
oped and approved also increases. By bringing clinicians, sci-
entists, regulatory bodies, and the pharmaceutical industry
working more closely together, this new era is likely to realize
the full potential of nanomedicine and further revolutionize
the healthcare system for the treatment of complex, rare, and
incurable diseases.
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